Sage files for an ap­proval for its ‘break­through’ ther­a­py for post­par­tum de­pres­sion

Sage Ther­a­peu­tics $SAGE is rolling the dice on their “break­through” drug for post­par­tum de­pres­sion.

The Cam­bridge, MA-based biotech has filed for an FDA ap­proval of brex­anolone IV, pitch­ing the ther­a­py in a shot at its first ever mar­ket­ed drug af­ter gain­ing the break­through drug path­way from both the FDA and the EMA.

Sage has field­ed pos­i­tive da­ta from two small late-stage stud­ies of a drug aimed at a ma­jor mar­ket which in­volves 10% to 20% of all moth­ers giv­ing birth in any giv­en year. But it al­so re­quires a 60-hour in­fu­sion pe­ri­od, rais­ing a re­mark­ably high hur­dle to adop­tion. Some an­a­lysts be­lieve that this will re­quire a home in­fu­sion kit to make it work com­mer­cial­ly, though Sage al­so has a pill form of the drug it’s push­ing in the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER